Home » Medical Devices » Drug Eluting Stents Market

Drug-Eluting Stents Market By Product Type (Polymer-Based Coating [Non-biodegradable Polymer-Based, Biodegradable Polymer-Based], Polymer-Free Coating, Microporous Surface, Microstructured Surface, Slotted Tubular Surface, Nanoporous Surface); By Application (Coronary Artery Diseases, Peripheral Artery Diseases); By End User (Hospitals, Ambulatory Surgical Centers) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Name: Drug Eluting Stents Market - Demand, Size and Competitive Analysis
Creator: Credence Research Inc.
Published: 2025-10-27
License: https://www.credenceresearch.com/info/privacy-policy
Keywords: Drug Eluting Stents Market

Summary
Table Of Content
Request Free Sample

Market Overview:

The Global Drug Eluting Stents Market size was valued at USD 5,571.7 million in 2018 to USD 8,805.3 million in 2024 and is anticipated to reach USD 16,087.9 million by 2032, at a CAGR of 7.85% during the forecast period.

REPORT ATTRIBUTE	DETAILS
Historical Period	2020-2023
Base Year	2024
Forecast Period	2025-2032
Drug-Eluting Stents Market Size 2024	USD 8,805.3 million
Drug-Eluting Stents Market, CAGR	7.85%
Drug-Eluting Stents Market Size 2032	USD 16,087.9 million

The market growth is driven by rising incidences of cardiovascular diseases and increasing demand for minimally invasive procedures. Continuous innovation in stent materials and coatings has improved biocompatibility and reduced restenosis rates. Growing preference for polymer-free and bioresorbable stents, along with expanding healthcare access in emerging economies, supports strong adoption across hospitals and cardiac centers globally.

North America dominates the Global Drug Eluting Stents Market due to advanced healthcare infrastructure and high treatment awareness. Europe follows with robust R&D investments and widespread clinical adoption. The Asia-Pacific region is emerging rapidly, fueled by increasing cardiovascular cases, rising healthcare expenditure, and improving medical device distribution networks, particularly in China, India, and Japan.

Drug Eluting Stents Market size

Market Insights:

The Global Drug Eluting Stents Market was valued at USD 5,571.7 million in 2018, reached USD 8,805.3 million in 2024, and is projected to reach USD 16,087.9 million by 2032, growing at a CAGR of 7.85% during the forecast period.
North America leads with a 33% market share due to advanced healthcare systems, robust reimbursement policies, and strong presence of global medical device manufacturers. Europe follows with 26%, supported by high adoption of biodegradable stents and extensive R&D investments, while Asia Pacific holds 27%, driven by rapid healthcare expansion and large patient populations.
Asia Pacific is the fastest-growing region with a CAGR of 8.0%, supported by increasing cardiovascular disease prevalence, expanding hospital infrastructure, and cost-effective production improving accessibility across major countries.
Hospitals dominate the market with about 72% share, driven by well-equipped cardiac units, skilled specialists, and growing procedural volumes in both developed and developing countries.
Ambulatory surgical centers account for nearly 28% share, benefiting from lower treatment costs, shorter recovery times, and increasing patient preference for minimally invasive cardiovascular procedures.

Access crucial information at unmatched prices!

Request your sample report today & start making informed decisions powered by Credence Research Inc.!

Download Sample

Market Drivers:

Rising Global Burden of Cardiovascular Diseases

The Global Drug Eluting Stents Market is driven by the growing incidence of cardiovascular diseases caused by sedentary lifestyles, unhealthy diets, and aging populations. Hospitals are witnessing a rise in angioplasty procedures, leading to greater demand for drug-eluting stents that reduce restenosis. Increasing awareness of early diagnosis and the availability of advanced interventional cardiology solutions also boost adoption. Government initiatives to expand cardiac care centers in emerging economies are strengthening treatment accessibility. Rising healthcare expenditure supports large-scale procurement of stents across public and private institutions.

For instance, Abbott’s XIENCE Skypoint stent achieved a 99% device success rate and demonstrated less than 1% stent thrombosis at 30 days in ST-elevation myocardial infarction patients, validated across multiple international clinical trials and patient registries.

Advancements in Stent Design and Coating Technologies

Technological innovations have significantly improved stent safety and performance in the Global Drug Eluting Stents Market. Modern stents use biodegradable polymers and next-generation coatings that allow controlled drug release and faster vessel healing. These improvements reduce the risks of late thrombosis and restenosis. Companies are focusing on thinner strut designs and flexible materials to enhance patient outcomes and procedure efficiency. Research into bioresorbable and polymer-free stents continues to open new growth avenues. Such innovations are fostering physician confidence and patient preference for advanced interventional therapies.

For instance, Boston Scientific’s Synergy stent platform reported very low target lesion failure and 0% stent thrombosis in real-world analysis, with a primary endpoint of less than 1% late loss confirmed in multicenter studies involving hundreds of patients.

Growing Preference for Minimally Invasive Cardiac Procedures

A strong shift toward minimally invasive treatments has been observed in the Global Drug Eluting Stents Market. Patients prefer procedures with shorter recovery times and fewer post-surgical complications. Drug-eluting stents align well with this demand, offering precise delivery and long-term vessel patency. Hospitals and clinics are investing in catheter-based technologies to meet this need efficiently. Increasing procedural success rates and reduced hospitalization costs encourage adoption among both patients and healthcare providers. Expanding access to skilled cardiologists also supports wider procedural acceptance globally.

Supportive Reimbursement and Healthcare Policies

Favorable healthcare policies are propelling growth in the Global Drug Eluting Stents Market. Governments and insurance providers are recognizing the cost-effectiveness of drug-eluting stents in reducing repeat interventions. National healthcare programs in developed countries ensure wider access to advanced coronary therapies. Developing nations are expanding insurance coverage for cardiac procedures to meet rising patient demand. Collaborative efforts between manufacturers and healthcare authorities are improving affordability and adoption. Supportive reimbursement frameworks are thus driving procedural volumes and sustaining market expansion worldwide.

Market Trends:

Shift Toward Bioresorbable and Polymer-Free Stents

A key trend in the Global Drug Eluting Stents Market is the transition to bioresorbable and polymer-free designs. These stents dissolve after vessel healing, minimizing long-term complications linked to permanent implants. The shift aligns with growing clinical interest in natural vessel restoration and reduced inflammatory response. Manufacturers are prioritizing development of stents with improved drug delivery kinetics and biodegradable coatings. Hospitals are increasingly adopting such products due to their superior biocompatibility. The trend signifies a move toward safer, next-generation coronary intervention technologies.

For instance, results from the landmark MASTER DAPT study, which included patients with high bleeding risk, showed that the Ultimaster and Ultimaster Tansei drug-eluting stents were safe for those on a shortened one-month course of dual antiplatelet therapy (DAPT). A separate 2024 registry focusing on an unselected Korean population treated with the Ultimaster stent reported specific 12-month outcomes, including a cardiac death rate of 1.5% and a stent thrombosis rate of 0.6%.

Integration of Nanotechnology and Smart Materials

The adoption of nanotechnology in the Global Drug Eluting Stents Market is redefining performance standards. Smart coatings embedded with nanomaterials allow controlled drug diffusion and enhanced healing responses. These coatings help prevent clot formation and inflammation while improving drug adherence to vessel walls. Continuous research in nanostructured alloys enhances flexibility and corrosion resistance. The use of intelligent materials also supports real-time monitoring and longer device lifespan. Such technological integration is driving innovation and shaping future design strategies in the market.

For instance, Biotronik’s Orsiro ultrathin strut drug-eluting stent delivered up to 40% lower target lesion failure versus Abbott’s Xience in three-year follow-up of the BIOFLOW-V trial, supported by US FDA approval and presented at major cardiology meetings.

Rise in Outpatient and Ambulatory Cardiac Interventions

The Global Drug Eluting Stents Market is witnessing an increase in outpatient-based cardiac procedures. Advancements in imaging, catheter systems, and anesthesia have made stenting procedures safer for same-day discharge. Hospitals are adopting cost-efficient models by shifting elective angioplasties to ambulatory centers. This approach lowers healthcare costs and improves patient convenience. Growing acceptance of radial artery access also supports quicker recovery and higher procedural success rates. The trend highlights the growing decentralization of interventional cardiology services.

Collaborative Research and Clinical Trials Expansion

R&D partnerships are expanding rapidly within the Global Drug Eluting Stents Market. Manufacturers are collaborating with academic institutions and hospitals to validate new product efficacy and long-term safety. Clinical studies focusing on novel drug formulations and coating compositions are accelerating regulatory approvals. The trend reflects industry commitment to evidence-based innovation. Increased clinical data availability improves physician confidence and supports broader adoption. Strategic collaborations continue to drive knowledge exchange and faster commercialization of new-generation stent technologies.

Market Challenges Analysis:

High Cost and Limited Access in Developing Regions

The Global Drug Eluting Stents Market faces challenges due to high treatment costs and limited accessibility in lower-income countries. The expensive nature of advanced stents restricts usage in resource-constrained healthcare systems. Limited reimbursement frameworks in emerging economies further impact affordability. Many hospitals rely on generic or bare-metal alternatives, slowing drug-eluting stent penetration. The lack of trained interventional cardiologists in rural areas adds another layer of difficulty. Manufacturers face pressure to balance innovation with cost-effectiveness while maintaining quality standards globally.

Regulatory Complexity and Long Approval Timelines

Regulatory hurdles are another key barrier in the Global Drug Eluting Stents Market. The stringent approval requirements for new stent materials and coatings prolong product launches. Variations in regional compliance frameworks create additional challenges for global distribution. Companies must conduct extensive clinical trials to prove safety and efficacy, delaying commercialization. The high cost of regulatory compliance discourages smaller firms from entering the market. Ongoing updates in device classification and testing norms further complicate product development and global rollout.

Market Opportunities:

Emerging Demand in Developing Healthcare Markets

The Global Drug Eluting Stents Market holds strong potential in emerging healthcare markets across Asia-Pacific, Latin America, and the Middle East. Rapid urbanization and growing awareness of cardiac health are increasing procedure volumes. Expanding medical infrastructure and investment in advanced catheterization labs are fueling regional adoption. Governments are improving reimbursement policies and supporting local manufacturing to ensure affordability. International players are partnering with regional firms to strengthen distribution networks and reach underserved populations. This rising demand is creating new avenues for market expansion.

Advancement in Biocompatible and Next-Generation Stent Technologies

The Global Drug Eluting Stents Market is witnessing opportunities through innovation in biocompatible and next-generation stent designs. Manufacturers are focusing on improving drug-release precision and vessel healing speed. Emerging materials such as magnesium and bioabsorbable polymers are gaining clinical acceptance. Continuous development of hybrid stent systems with digital monitoring capabilities enhances patient safety. Growing interest in precision-based cardiovascular treatments and hospital modernization will continue to drive future market expansion globally.

Market Segmentation Analysis:

By Product Type

The Global Drug Eluting Stents Market is segmented by product type into polymer-based and polymer-free coatings. Polymer-based coatings include non-biodegradable and biodegradable variants, which dominate due to their controlled drug-release properties and proven clinical outcomes. Non-biodegradable stents offer longer durability, while biodegradable ones reduce late-stage thrombosis risks. Polymer-free coatings, featuring microporous, microstructured, slotted tubular, and nanoporous surfaces, are gaining traction for their superior biocompatibility and faster vessel healing. Continuous innovation in surface engineering and material science supports the shift toward next-generation stent designs.

By Application

The market is classified by application into coronary artery diseases and peripheral artery diseases. Coronary artery disease remains the leading segment due to the high global burden of ischemic heart conditions and widespread use of percutaneous coronary interventions. Drug-eluting stents play a critical role in reducing restenosis rates and improving patient survival outcomes. Peripheral artery disease applications are expanding steadily with rising adoption in limb revascularization procedures. Increasing awareness and advancements in minimally invasive interventions strengthen market growth across both segments.

For instance, Medtronic’s Onyx Frontier stent received FDA approval for treating non-left main bifurcation coronary lesions and has shown improved procedure success rates with enhanced deliverability, as validated by recent regulatory filings and published product information.

By End User

The end-user segmentation of the Global Drug Eluting Stents Market includes hospitals and ambulatory surgical centers. Hospitals account for a major share, driven by advanced infrastructure, skilled cardiologists, and access to high-end interventional technologies. Ambulatory surgical centers are witnessing growing demand due to shorter recovery times and cost-efficient procedures. The ongoing decentralization of cardiac care and rising preference for outpatient treatments support expansion across both segments globally.

Drug Eluting Stents Market segmentation

Segmentation:

By Product Type:

Polymer-Based Coating
- Non-biodegradable Polymer-Based
- Biodegradable Polymer-Based
Polymer-Free Coating
- Microporous Surface
- Microstructured Surface
- Slotted Tubular Surface
- Nanoporous Surface

By Application:

Coronary Artery Diseases
Peripheral Artery Diseases

By End User:

Hospitals
Ambulatory Surgical Centers

By Region:

North America
- U.S.
- Canada
Europe
- Germany
- France
- Italy
- U.K.
- Russia
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East and Africa
- GCC Countries
- South Africa
- Rest of Middle East and Africa

Regional Analysis:

North America

The North America Global Drug Eluting Stents Market size was valued at USD 1,839.78 million in 2018 to USD 2,872.43 million in 2024 and is anticipated to reach USD 5,162.61 million by 2032, at a CAGR of 7.6% during the forecast period. North America holds the largest regional share in the market, accounting for nearly 33% of global revenue. The region benefits from advanced healthcare infrastructure, a strong reimbursement framework, and widespread awareness of cardiovascular treatments. The U.S. leads with high procedure volumes, supported by early adoption of innovative stent technologies. Favorable regulatory approvals and strong presence of key manufacturers drive consistent product launches. Canada and Mexico are witnessing growing demand due to rising cardiac cases and investments in medical facilities. Continuous research collaborations and clinical trials further strengthen the regional position in global market growth.

Europe

The Europe Global Drug Eluting Stents Market size was valued at USD 1,380.67 million in 2018 to USD 2,219.70 million in 2024 and is anticipated to reach USD 4,147.47 million by 2032, at a CAGR of 8.2% during the forecast period. Europe accounts for nearly 26% of the global market share. The region’s growth is driven by a high prevalence of coronary artery diseases, well-established cardiac care centers, and increased healthcare spending. Germany, France, and the UK lead due to advanced medical infrastructure and adoption of biodegradable stent technologies. Favorable regulatory policies under the European Medical Device Regulation (MDR) framework support innovation and product safety. Expansion of cardiovascular research initiatives enhances regional market competitiveness. Growing patient preference for minimally invasive treatments continues to strengthen demand across hospitals and surgical centers.

Asia Pacific

The Asia Pacific Global Drug Eluting Stents Market size was valued at USD 1,466.47 million in 2018 to USD 2,336.43 million in 2024 and is anticipated to reach USD 4,314.78 million by 2032, at a CAGR of 8.0% during the forecast period. The region holds approximately 27% of the global share and represents the fastest-expanding market base. Rising incidences of cardiovascular diseases, expanding healthcare infrastructure, and favorable government programs are fueling growth. China, Japan, and India are key contributors due to large patient populations and increased healthcare investments. Local manufacturing capabilities and lower production costs attract global players to establish partnerships. Growing awareness of early diagnosis and availability of affordable stent options are boosting adoption. Technological innovations and medical tourism further strengthen regional market development.

Latin America

The Latin America Global Drug Eluting Stents Market size was valued at USD 407.85 million in 2018 to USD 628.32 million in 2024 and is anticipated to reach USD 1,108.46 million by 2032, at a CAGR of 7.4% during the forecast period. The region contributes about 7% to the global market share. Increasing healthcare reforms, expanding private hospital networks, and improving access to interventional cardiology procedures are driving market expansion. Brazil remains the primary market leader, supported by a strong public health system and emerging medical device distributors. Mexico and Argentina are experiencing growing adoption of modern cardiovascular devices. Regional demand is also supported by training programs aimed at improving procedural expertise. International collaborations and investments in healthcare modernization are fostering long-term market growth.

Middle East

The Middle East Global Drug Eluting Stents Market size was valued at USD 322.04 million in 2018 to USD 510.46 million in 2024 and is anticipated to reach USD 936.32 million by 2032, at a CAGR of 7.9% during the forecast period. The region accounts for nearly 5% of the global market share. Increasing cardiovascular disease prevalence, coupled with government initiatives for healthcare diversification, supports rapid market development. Gulf Cooperation Council (GCC) countries lead due to high healthcare spending and adoption of advanced stent systems. Investments in cardiac specialty hospitals and collaborations with global medical device manufacturers are improving treatment availability. Israel and Turkey are witnessing strong clinical research activity, supporting innovative product introduction. Growing awareness and regional health infrastructure development continue to enhance the market outlook.

Africa

The Africa Global Drug Eluting Stents Market size was valued at USD 154.89 million in 2018 to USD 238.00 million in 2024 and is anticipated to reach USD 418.29 million by 2032, at a CAGR of 7.3% during the forecast period. Africa represents nearly 3% of the global market share, driven by gradual improvements in healthcare infrastructure and access to cardiac treatment facilities. South Africa leads due to higher healthcare investments and expanding interventional cardiology practices. Egypt follows with rising awareness of coronary disease management and urban healthcare development. Limited affordability and shortage of skilled cardiologists remain key challenges. International aid programs and private-sector participation are helping improve accessibility and device availability. The growing prevalence of lifestyle-related heart diseases continues to create long-term market opportunities across the continent.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key Player Analysis:

Abbott
Biotronik SE & Co. KG
Reva Medical Inc.
Elixir Medical Corporation
Kyoto Medical Planning Co., Ltd
Braun
Medtronic
Terumo Corporation
Meril Life Sciences
Boston Scientific Corporation

Competitive Analysis:

The Global Drug Eluting Stents Market is characterized by intense competition among major medical device manufacturers focusing on innovation and clinical reliability. Companies such as Abbott, Boston Scientific, Medtronic, and Terumo dominate the landscape through strong product portfolios and extensive R&D investments. It is driven by continuous improvement in polymer coatings, stent materials, and drug-release technologies. Emerging players are focusing on cost-effective bioresorbable solutions to capture unmet demand in developing economies. Strategic collaborations, acquisitions, and clinical trials are shaping competitive positioning. Product differentiation and regulatory compliance remain key determinants of long-term success.

Recent Developments:

In September 2025, Abbott received Health Canada approval for the Esprit BTK Everolimus Eluting Resorbable Scaffold System—a new-generation dissolving stent designed for use below the knee. This product delivers the anti-proliferative drug Everolimus to support vessel healing prior to completely dissolving, advancing options for peripheral arterial disease treatment.
In June 2025, Teleflex completed the €760 million acquisition of BIOTRONIK’s Vascular Intervention business, which includes the Freesolve drug-eluting resorbable stent (CE mark received in 2024) and Orsiro Mission Drug Eluting Stent. This move expands Teleflex’s suite for coronary and peripheral interventions and positions the acquired portfolio for global commercialization.
In 2025, Elixir Medical announced the launch of its LithiX™ Hertz Contact (HC) Intravascular Lithotripsy System in Europe. This novel device uses advanced lithotripsy technology to fragment calcium plaque for easier stent deployment. Additionally, late-breaking clinical trial results at EuroPCR 2025 showed the DynamX® Bioadaptor sustained significantly lower target lesion failure rates (2.7% vs. 7.2%) and lower cardiac death rates (0.5% vs. 3.2%) over three years compared to conventional drug-eluting stents, highlighting its efficacy in complex coronary cases.
In October 2025, Medtronic continued worldwide expansion of its Onyx Frontier Drug-Eluting Stent, featuring enhanced delivery for interventional cardiologists, following earlier FDA and CE mark approvals. The stent’s broad platform supports advanced vascular procedures for diverse patient needs.
In October 2025, Terumo Aortic announced a collaboration with Bentley for a groundbreaking clinical study, while Terumo Neuro launched the Aneurysm Treatment Alliance at ESMINT 2025. These initiatives reinforce the company’s commitment to innovative neurovascular and hemorrhagic solutions, including drug-eluting stent advancements.

Report Coverage:

The research report offers an in-depth analysis based on product type, application, and end user. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook:

Demand will continue to rise with growing global cardiovascular disease prevalence.
Biodegradable and polymer-free stents will gain rapid clinical acceptance.
Asia Pacific will emerge as a leading growth hub supported by healthcare modernization.
Technological integration with imaging and diagnostic systems will enhance treatment precision.
Strategic partnerships between OEMs and hospitals will expand access in developing regions.
Innovation in drug coatings will improve healing rates and reduce thrombosis risks.
Digital health integration will optimize post-procedure monitoring and data collection.
Regulatory harmonization across regions will accelerate product approvals.
Market consolidation through mergers will strengthen competitive positioning.
Sustainable manufacturing and cost-optimized production will shape long-term profitability.

CHAPTER NO. 1 : GENESIS OF THE MARKET

1.1 Market Prelude – Introduction & Scope

1.2 The Big Picture – Objectives & Vision

1.3 Strategic Edge – Unique Value Proposition

1.4 Stakeholder Compass – Key Beneficiaries

CHAPTER NO. 2 : EXECUTIVE LENS

2.1 Pulse of the Industry – Market Snapshot

2.2 Growth Arc – Revenue Projections (USD Million)

2.3. Premium Insights – Based on Primary Interviews

CHAPTER NO. 3 : DRUG ELUTING STENTS MARKET FORCES & INDUSTRY PULSE

3.1 Foundations of Change – Market Overview
3.2 Catalysts of Expansion – Key Market Drivers
3.2.1 Momentum Boosters – Growth Triggers
3.2.2 Innovation Fuel – Disruptive Technologies
3.3 Headwinds & Crosswinds – Market Restraints
3.3.1 Regulatory Tides – Compliance Challenges
3.3.2 Economic Frictions – Inflationary Pressures
3.4 Untapped Horizons – Growth Potential & Opportunities
3.5 Strategic Navigation – Industry Frameworks
3.5.1 Market Equilibrium – Porter’s Five Forces
3.5.2 Ecosystem Dynamics – Value Chain Analysis
3.5.3 Macro Forces – PESTEL Breakdown

CHAPTER NO. 4 : KEY INVESTMENT EPICENTER

4.1 Regional Goldmines – High-Growth Geographies

4.2 Product Frontiers – Lucrative Product Categories

4.3 End User Sweet Spots – Emerging Demand Segments

CHAPTER NO. 5: REVENUE TRAJECTORY & WEALTH MAPPING

5.1 Momentum Metrics – Forecast & Growth Curves

5.2 Regional Revenue Footprint – Market Share Insights

5.3 Segmental Wealth Flow – Product, Application, and End User Revenue

CHAPTER NO. 6 : TRADE & COMMERCE ANALYSIS

6.1. Import Analysis By Region

6.1.1. Global Drug Eluting Stents Market Import Revenue By Region

6.2. Export Analysis By Region

6.2.1. Global Drug Eluting Stents Market Export Revenue By Region

CHAPTER NO. 7 : COMPETITION ANALYSIS

7.1. Company Market Share Analysis

7.1.1. Global Drug Eluting Stents Market: Company Market Share

7.2. Global Drug Eluting Stents Market Company Revenue Market Share

7.3. Strategic Developments

7.3.1. Acquisitions & Mergers

7.3.2. New Product Launch

7.3.3. Regional Expansion

7.4. Competitive Dashboard

7.5. Company Assessment Metrics, 2024

CHAPTER NO. 8 : DRUG ELUTING STENTS MARKET – BY PRODUCT SEGMENT ANALYSIS

8.1. Drug Eluting Stents Market Overview By Product Segment

8.1.1. Drug Eluting Stents Market Revenue Share By Product

8.2. Polymer-Based Coating

8.2.1. Non-biodegradable Polymer-based

8.2.2. Biodegradable Polymer-based

8.3. Polymer-Free Coating

8.3.1. Microporous Surface

8.3.2. Microstructured Surface

8.3.3. Slotted Tubular Surface

8.3.4. Nanoporous Surface

CHAPTER NO. 9 : DRUG ELUTING STENTS MARKET – BY APPLICATION SEGMENT ANALYSIS

9.1. Drug Eluting Stents Market Overview By Application Segment

9.1.1. Drug Eluting Stents Market Revenue Share By Application

9.2. Coronary artery diseases

9.3. Peripheral artery diseases

CHAPTER NO. 10 : DRUG ELUTING STENTS MARKET – BY END USER SEGMENT ANALYSIS

10.1. Drug Eluting Stents Market Overview By End User Segment

10.1.1. Drug Eluting Stents Market Revenue Share By End User

10.2. Hospitals

10.3. Ambulatory Surgical Centers

CHAPTER NO. 11 : DRUG ELUTING STENTS MARKET – REGIONAL ANALYSIS

11.1. Drug Eluting Stents Market Overview By Region Segment

11.1.1. Global Drug Eluting Stents Market Revenue Share By Region

10.1.2. Regions

11.1.3. Global Drug Eluting Stents Market Revenue By Region

11.1.4. Product

11.1.5. Global Drug Eluting Stents Market Revenue By Product

11.1.6. Application

11.1.7. Global Drug Eluting Stents Market Revenue By Application

11.1.8. End User

11.1.9. Global Drug Eluting Stents Market Revenue By End User

CHAPTER NO. 12 : NORTH AMERICA DRUG ELUTING STENTS MARKET – COUNTRY ANALYSIS

12.1. North America Drug Eluting Stents Market Overview By Country Segment

12.1.1. North America Drug Eluting Stents Market Revenue Share By Region

12.2. North America

12.2.1. North America Drug Eluting Stents Market Revenue By Country

12.2.2. Product

12.2.3. North America Drug Eluting Stents Market Revenue By Product

12.2.4. Application

12.2.5. North America Drug Eluting Stents Market Revenue By Application

12.2.6. End User

12.2.7. North America Drug Eluting Stents Market Revenue By End User

12.3. U.S.

12.4. Canada

12.5. Mexico

CHAPTER NO. 13 : EUROPE DRUG ELUTING STENTS MARKET – COUNTRY ANALYSIS

13.1. Europe Drug Eluting Stents Market Overview By Country Segment

13.1.1. Europe Drug Eluting Stents Market Revenue Share By Region

13.2. Europe

13.2.1. Europe Drug Eluting Stents Market Revenue By Country

13.2.2. Product

13.2.3. Europe Drug Eluting Stents Market Revenue By Product

13.2.4. Application

13.2.5. Europe Drug Eluting Stents Market Revenue By Application

13.2.6. End User

13.2.7. Europe Drug Eluting Stents Market Revenue By End User

13.3. UK

13.4. France

13.5. Germany

13.6. Italy

13.7. Spain

13.8. Russia

13.9. Rest of Europe

CHAPTER NO. 14 : ASIA PACIFIC DRUG ELUTING STENTS MARKET – COUNTRY ANALYSIS

14.1. Asia Pacific Drug Eluting Stents Market Overview By Country Segment

14.1.1. Asia Pacific Drug Eluting Stents Market Revenue Share By Region

14.2. Asia Pacific

14.2.1. Asia Pacific Drug Eluting Stents Market Revenue By Country

14.2.2. Product

14.2.3. Asia Pacific Drug Eluting Stents Market Revenue By Product

14.2.4. Application

14.2.5. Asia Pacific Drug Eluting Stents Market Revenue By Application

14.2.6. End User

14.2.7. Asia Pacific Drug Eluting Stents Market Revenue By End User

14.3. China

14.4. Japan

14.5. South Korea

14.6. India

14.7. Australia

14.8. Southeast Asia

14.9. Rest of Asia Pacific

CHAPTER NO. 15 : LATIN AMERICA DRUG ELUTING STENTS MARKET – COUNTRY ANALYSIS

15.1. Latin America Drug Eluting Stents Market Overview By Country Segment

15.1.1. Latin America Drug Eluting Stents Market Revenue Share By Region

15.2. Latin America

15.2.1. Latin America Drug Eluting Stents Market Revenue By Country

15.2.2. Product

15.2.3. Latin America Drug Eluting Stents Market Revenue By Product

15.2.4. Application

15.2.5. Latin America Drug Eluting Stents Market Revenue By Application

15.2.6. End User

15.2.7. Latin America Drug Eluting Stents Market Revenue By End User

15.3. Brazil

15.4. Argentina

15.5. Rest of Latin America

CHAPTER NO. 16 : MIDDLE EAST DRUG ELUTING STENTS MARKET – COUNTRY ANALYSIS

16.1. Middle East Drug Eluting Stents Market Overview By Country Segment

16.1.1. Middle East Drug Eluting Stents Market Revenue Share By Region

16.2. Middle East

16.2.1. Middle East Drug Eluting Stents Market Revenue By Country

16.2.2. Product

16.2.3. Middle East Drug Eluting Stents Market Revenue By Product

16.2.4. Application

16.2.5. Middle East Drug Eluting Stents Market Revenue By Application

16.2.6. End User

16.2.7. Middle East Drug Eluting Stents Market Revenue By End User

16.3. GCC Countries

16.4. Israel

16.5. Turkey

16.6. Rest of Middle East

CHAPTER NO. 17 : AFRICA DRUG ELUTING STENTS MARKET – COUNTRY ANALYSIS

17.1. Africa Drug Eluting Stents Market Overview By Country Segment

17.1.1. Africa Drug Eluting Stents Market Revenue Share By Region

17.2. Africa

17.2.1. Africa Drug Eluting Stents Market Revenue By Country

17.2.2. Product

17.2.3. Africa Drug Eluting Stents Market Revenue By Product

17.2.4. Application

17.2.5. Africa Drug Eluting Stents Market Revenue By Application

17.2.6. End User

17.2.7. Africa Drug Eluting Stents Market Revenue By End User

17.3. South Africa

17.4. Egypt

17.5. Rest of Africa

CHAPTER NO. 18 : COMPANY PROFILES

18.1. Abbott

18.1.1. Company Overview

18.1.2. Product Portfolio

18.1.3. Financial Overview

18.1.4. Recent Developments

18.1.5. Growth Strategy

18.1.6. SWOT Analysis

18.2. Biotronik SE & Co. KG

18.3. Reva Medical Inc.

18.4. Elixir Medical Corporation

18.5. Kyoto Medical Planning Co., Ltd

18.6. B. Braun

18.7. Medtronic

18.8. Terumo Corporation

18.9. Meril Life Sciences

18.10. Boston Scientific Corporation

18.11. Other Key Players

Request A Free Sample

We prioritize the confidentiality and security of your data. Our promise: your information remains private.

Ready to Transform Data into Decisions?

Request Your Sample Report and Start Your Journey of Informed Choices

Providing the strategic compass for industry titans.

Frequently Asked Questions

What is the current market size for Global Drug Eluting Stents Market, and what is its projected size in 2032?

The Global Drug Eluting Stents Market was valued at USD 5,571.7 million in 2018 and reached USD 8,805.3 million in 2024. It is projected to reach USD 16,087.9 million by 2032, reflecting steady expansion across key regions.

At what Compound Annual Growth Rate is the Global Drug Eluting Stents Market projected to grow between 2025 and 2032?

The market is expected to grow at a CAGR of 7.85% during the forecast period. Continuous innovation, growing cardiovascular disease cases, and expanding healthcare infrastructure drive consistent market growth.

Which Global Drug Eluting Stents Market segment held the largest share in 2024?

The polymer-based coating segment held the largest share in 2024. Its dominance stems from high clinical reliability, controlled drug-release performance, and widespread use in coronary interventions.

What are the primary factors fueling the growth of the Global Drug Eluting Stents Market?

Key growth drivers include rising cardiovascular disease incidence, increasing demand for minimally invasive procedures, technological innovation in stent design, and favorable reimbursement policies across developed markets.

Who are the leading companies in the Global Drug Eluting Stents Market?

Prominent players include Abbott, Boston Scientific Corporation, Medtronic, Terumo Corporation, and Biotronik SE & Co. KG. These companies maintain leadership through continuous R&D investments and global market expansion.

Who are the major players in this Market?

Abbott Laboratories Inc.,Biosensors International Group,Biotronik,Boston Scientific Corporation,Cook Medical are some of the major players in the global market.

About Author

Shweta Bisht

Healthcare & Biotech Analyst

Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.

View Profile

Related Reports

Multiparameter Patient Monitoring Market

The Multiparameter Patient Monitoring market reached USD 12.9 billion in 2024 and is projected to achieve USD 19.97 billion by 2032. The market is expected to grow at a CAGR of 5.62% during the forecast period.

Cardiac Resynchronization Therapy (CRT) Devices Market

Cardiac Resynchronization Therapy (CRT) Devices Market size was valued USD 4.68 billion in 2024 and is anticipated to reach USD 7.02 billion by 2032, at a CAGR of 5.2% during the forecast period.

UV Irradiation Cabins Market

UV irradiation cabins market was valued at USD 1197.5 million in 2024 and is anticipated to reach USD 2386.09 million by 2032, growing at a CAGR of 9% during the forecast period.

Lab Automation Clinical Diagnostic Market

Lab Automation in Clinical Diagnostics market size was valued at USD 7.87 Billion in 2024 and is anticipated to reach USD 12.99 Billion by 2032, at a CAGR of 6.47% during the forecast period.

Microwave Ablation System Market

Microwave Ablation System Market size was valued USD 460.55 million in 2024 and is anticipated to reach USD 1143.57 million by 2032, at a CAGR of 12.04% during the forecast period.

Huber Needles Market

Huber Needles Market size was valued USD 62.1 million in 2024 and is anticipated to reach USD 83.69 million by 2032, at a CAGR of 3.8% during the forecast period.

Chiral Chromatography Columns Market

Chiral Chromatography Columns Market size was valued USD 120.2 million in 2024 and is anticipated to reach USD 163.24 million by 2032, at a CAGR of 3.9% during the forecast period.

Lateral Epicondylitis (Tennis Elbow) Market

Lateral Epicondylitis Tennis Elbow Market was valued at USD 1197.5 million in 2024 and is anticipated to reach USD 1865.84 million by 2032, growing at a CAGR of 5.7% during the forecast period.

Breast Biopsy Devices Market

Breast Biopsy Devices Market was valued at USD 1087.5 million in 2024 and is anticipated to reach USD 1484.89 million by 2032, growing at a CAGR of 3.97 % during the forecast period.

Refractometer Market

Refractometer Market was valued at USD 495 million in 2024 and is anticipated to reach USD 748.22 million by 2032, growing at a CAGR of 5.3 % during the forecast period.

Sterile Tube Welder Market

Sterile Tube Welder Market size was valued USD 2.63 Billion in 2024 and is anticipated to reach USD 3.8 Billion by 2032, at a CAGR of 4.71% during the forecast period.

Non-Hormonal Alternatives for Menopause Market

Non Hormonal Alternatives For Menopause Market size was valued USD 9821 million in 2024 and is anticipated to reach USD 17386.44 million by 2032, at a CAGR of 7.4% during the forecast period.

Licence Option

Single User

$4999

Multi User

$6999

Enterprise

$12999

Report delivery within 24 to 48 hours

Let us help you

WILLIAM, North America

+1 304 308 1216

KEITH PHILLIPS, Europe

+44 7809 866 263

LEE VALLANCE, Asia Pacific

+64 22 017 0275

KIERAN JAMESON, Australia

+61 4192 46279

Request A Free Sample

What people say?

Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.

Materials Scientist
(privacy requested)

The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.

Imre Hof
Management Assistant, Bekaert

Trusted By

Request Sample